Showing 6361-6370 of 7650 results for "".
- PE-Backed Ownership of Dermatology Practices Is On The Risehttps://practicaldermatology.com/news/pe-backed-ownership-of-dermatology-practices-is-on-the-rise/2460104/Private equity firms have increased their financial stakes in dermatology practices throughout the United States, but exactly how this affects care is not fully understood yet. Private equity-backed dermatology management groups acquired 184 dermatology practices from 2012 to 2018, with
- Vehicles, Infectious Disease, and Acne Updates from Day 2 at DERM2019https://practicaldermatology.com/news/vehicles-infectious-disease-and-acne-updates-from-day-2-at-derm2019/2460099/The DERM2019 NP/PA CME Conference continued to delight audiences with esteemed faculty presenters, including those who presented Friday, including April Armstrong, David Cohen, Kara Gooding, Joseph Gorelick, Julie Harper, Jayme Heim, George Keough, Leon Kircik, Kristine Kucera, Gilly Munavalli, T
- Psoriasis, Psoriatic Arthritis, and AD Updates from Day 1 at DERM2019https://practicaldermatology.com/news/psoriasis-psoriatic-arthritis-and-ad-updates-from-day-1-at-derm2019/2460098/The first day of the DERM2019 NP/PA CME Conference kicked off with a bang! Exciting talks and lively panel discussions from April Armstrong, David Cohen, Adam Friedman, Kara Gooding, and Joe Gorelick were the mainstay of the day. Psoriasis Pathogenesis and Treatment T
- Revance Adds New Member to Board of Directorshttps://practicaldermatology.com/news/revance-adds-new-member-to-board-of-directors/2460096/Chris Nolet is the newest member of Revance Therapeutics, Inc.’s Board of Directors. He will serve as the Chair of the Revance Audit Committee. “Chris Nolet brings an extraordinary record of industry-shaping consultation to the Revance Bo
- Novartis Offers Free Genetic Testing for Advanced Melanomahttps://practicaldermatology.com/news/novartis-offers-free-genetic-testing-for-advanced-melanoma/2460095/The Know Now Testing Program is an initiative from Novartis in collaboration with Quest Diagnostics that offers genetic mutation testing at no cost for all patients with stage III or stage IV melanoma. Nearly half of all advanced melanoma patients carry a specific mutation, called BRAF.
- Second US Patent Issued to Alastin Based On TriHex Technologyhttps://practicaldermatology.com/news/second-us-patent-issued-to-alastin-based-on-trihex-technology/2460092/Alastin Skincare, Inc. was issued a second U.S. Patent, No. 10,286,030 from the United States Patent and Trademark Office covering Alastin's platform TriHex Technology. The patent also covers a variety of topical compositions based on Alastin's TriHex Technology. The coma
- AARS Survey Uncovers Real Impact Of Acne On Young Professionalshttps://practicaldermatology.com/news/aars-survey-uncovers-real-impact-of-acne-on-young-professionals/2460087/Results of a recent American Acne and Rosacea Society (AARS) survey highlight the significant health burden and everyday impact of acne on young professionals. According to the survey of 1,004 men and women between the ages of 22 and 30 conducted by The Harris Poll, many people whose acne persist
- Phase 3b/4 Study ANSWERs Rosacea Therapy Questionshttps://practicaldermatology.com/news/phase-3b4-study-answers-rosacea-therapy-questions/2460082/Results of the phase 3b/4 ANSWER study, recently published onlinein the Journal of the American Academy of Dermatology, show that concomitant use of Oracea Capsules and Soolantra Cream provided significan
- Duobrii Lotion for Plaque Psoriasis Hits Shelveshttps://practicaldermatology.com/news/duobrii-lotion-for-plaque-psoriasis-hits-shelves/2460079/Ortho Dermatologics’ Duobrii (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, is now available. Approved by the U.S. Food and Drug Administration on April 25, 2019, Duobrii is the first and only topical lotion that contains a uniq
- BioPharmX’s BPX-04 Performs Well in Rosacea Trialhttps://practicaldermatology.com/news/biopharmxs-bpx-04-performs-well-in-rosacea-trial/2460078/BioPharmX Corporation ‘s BPX-04, a novel topical gel formulation of fully solubilized minocycline for the treatment of moderate-to-severe papulopustular rosacea, performed well in a Phase 2b clinical trial, the Company reports. In the trial,